BOSTON, MA — Liferna today announced that it will host its inaugural R&D Day on June 18, 2026, providing a comprehensive look at the company’s clinical pipeline, scientific platforms, and long-term development strategy.
The event will feature presentations from members of Liferna’s executive team and external clinical experts, with deep dives on:
- The LFR-401 oncology program, including Phase 2 design in cervical cancer and ongoing ADC combinations in NSCLC, TNBC, and PROC
- LFR-201 development across IPF and systemic sclerosis
- Liferna’s biologics and small molecule technology platforms
- Strategic partnerships powering capital-efficient development
The R&D Day will be webcast live and a replay will be made available through Liferna’s investor relations site. Patients, advocacy groups, and members of the medical community are also invited to attend.
“This is the right moment to share, in depth, what we are building. Our pipeline is differentiated, our partnerships are strong, and our strategy is sharply focused on patients who need new options most.”